These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7173929)

  • 1. N-acetylation phenotype in bladder cancer.
    Woodhouse KW; Adams PC; Clothier A; Mucklow JC; Rawlins MD
    Hum Toxicol; 1982 Oct; 1(4):443-5. PubMed ID: 7173929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population.
    Mommsen S; Barfod NM; Aagaard J
    Carcinogenesis; 1985 Feb; 6(2):199-201. PubMed ID: 3971485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers.
    Rothman N; Bhatnagar VK; Hayes RB; Zenser TV; Kashyap SK; Butler MA; Bell DA; Lakshmi V; Jaeger M; Kashyap R; Hirvonen A; Schulte PA; Dosemeci M; Hsu F; Parikh DJ; Davis BB; Talaska G
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5084-9. PubMed ID: 8643532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation phenotypes and bladder cancer.
    Hanke J; Krajewska B
    J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.
    Marcus PM; Vineis P; Rothman N
    Pharmacogenetics; 2000 Mar; 10(2):115-22. PubMed ID: 10761999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype in human bladder cancer.
    Miller ME; Cosgriff JM
    J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.
    Hayes RB; Bi W; Rothman N; Broly F; Caporaso N; Feng P; You X; Yin S; Woosley RL; Meyer UA
    Carcinogenesis; 1993 Apr; 14(4):675-8. PubMed ID: 8472331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
    Wolf H; Lower GM; Bryan GT
    Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acetyltransferase phenotype of patients with bladder cancer.
    Karakaya AE; Cok I; Sardas S; Gögüs O; Sardas OS
    Hum Toxicol; 1986 Sep; 5(5):333-5. PubMed ID: 3770769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of isoniazid: influence of age.
    Kergueris MF; Bourin M; Larousse C
    Eur J Clin Pharmacol; 1986; 30(3):335-40. PubMed ID: 3732371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.